Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits

Thrombosis Research

Volumn 101, Issue 3, 2001, Pages 159-170

  Elg, Margareta ^a   Carlsson, Stefan ^a   Gustafsson, David ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Antidote; Bleeding time; Melagatran; Rabbits; Rats; Thrombin inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; APROTININ; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; HAEMATE; MELAGATRAN; PROTHROMBIN COMPLEX; PROTHROMPLEX T; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; THROMBIN INHIBITOR; TRANEXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING DISORDER; BLEEDING TIME; BLOOD CLOTTING TIME; CONTROLLED STUDY; HEMOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; STATISTICAL ANALYSIS;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BLEEDING TIME; BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIIA; FACTOR VIII; GLYCINE; HEMORRHAGE; HUMANS; RABBITS; RATS; THROMBIN; VON WILLEBRAND FACTOR;

EID: 0035251738     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00398-4     Document Type: Article

References (34)

1. Protamine - Antagonist to heparin
2. 1 reduction in human liver
3. 1 in oral anticoagulant reversal
4. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro
5. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CPG 39393) on bleeding in the rat
6. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models
7. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
8. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic low-molecular-weight thrombin inhibitor, in patients with acute deep vein thrombosis
9. Subcutaneous and oral direct thrombin inhibitors for prophylaxis of deep venous thrombosis and pulmonary embolism after total hip and knee replacement
10. Clinical application of inhibitors of fibrinolysis
11. Effects of aprotinin on coagulation and fibrinolysis enzymes
12. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years
13. A multicentre study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previous untreated patients with haemophilia A
14. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease
15. Efficacy of a high-purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery
16. Clinical experience with recombinant factor VIIa
17. Multicenter retrospective study on the utilization of Feiba in France in patients with factor VIII and factor IX inhibitors
18. Measurement of active coagulation factors in Autoplex-T with colorimetric active site-specific assay technology
19. Biochemical and in vivo properties of high-purity factor IX concentrates
20. Effects of inogatran, a low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time
21. Determination of free haemoglobin in serum by an automated assay using 4-aminphenazone and the Cobas Bio System
22. Bleeding time in laboratory animals: II. A comparison of different assay conditions in rats
23. A critical reappraisal of the bleeding time
24. Standardization of the bleeding time
25. A canine model of hemophilic (factor VIII: C deficiency) bleeding
26. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model
27. Human factor IX corrects the bleeding diathesis of mice with hemophilia B
28. Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat
29. Aprotinin: An antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivo
30. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat
31. Aprotinin prolongs whole blood activated partial thromboplastin time but not whole blood prothrombin time in patients undergoing cardiac surgery
32. Mechanism by which recombinant factor VIIa shortens the aPTT: Activation of factor X in the absence of tissue factor
33. Assessment of bleeding for evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease
34. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor